|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Insomnia - Targeting The Sleep Maintenance Market
Datamonitor, April 2007, Pages: 240
The launch of serotonin antagonists which are largely aimed at treating sleep maintenance is set to make a substantial impact on the insomnia market, which will increase in value across the seven major markets from $6.1 billion in 2006 to $7.7 billion in 2016.
Scope of this title:
Analysis of patient potential, unmet needs and clinical trial design in insomnia
Overview of drugs in late- and early-stage clinical development; with analysis of key companies involved in the R&D pipeline
Detailed profiles of key compounds in development for use in insomnia, with forecasts of drug revenues to 2016
Discussion of Sanofi-Aventis and Neurocrines strategies, and insight from key industry opinion leaders
Highlights of this title:
Serotonin receptor antagonists are the most prevalent drug clasWe predict that serotonin antagonist companies will be important players in the market in the future, led by Sanofi-Aventis eplivanserin. The majority of pipeline drugs are being investigated for sleep maintenance as opposed to sleep onset insomnia and there is a trend towards the development of drugs for the treatment of co-morbid disorders. In March 2007, Merck & Co. and Lundbeck discontinued development of their Phase III drug, gaboxadol, due to disappointing trial results. Although this is a considerable blow to Lundbeck, the reduction in competition is positive news for current and future insomnia market players.
Reasons to order your copy:
Understand unmet needs in the insomnia market based on key opinion leader comments
Benchmark key late-stage insomnia compounds against current market leaders
Assess the global (US, Japan, five major EU) sales forecasts of key late-stage pipeline drugs; and examine their clinical and commercial potential
Customers who bought this item also bought
Pipeline and Commercial Perspectives: Insomnia
Commercial Insight: Insomnia Strong brand identity critical to differentiation in an increasingly crowded market
Forecast Insight: Insomnia Orexin and Serotonin Receptor Modulators to Innovate Market
Sleep Disorders: Insomnia, Sleep Apnea, Restless Leg Syndrome, Bruxism, Narcolepsy and Sleepwalking
Central Nervous System - Insomnia or Sleep Disorders Drug Pipeline Report
Insomnia or Sleep Disorders Therapy Area Pipeline Report
Insomnia - Sanofi-Synthelabo to Drive Growth of This Potentially Lucrative Market
Insomnia: Wake-Up Call for a Sleepy Market
U.S. Insomnia Therapies Markets
Commercial Perspectives: Sleep Disorders - Insomnia, Narcolepsy and Restless Leg Syndrome
Target Product Profiles 2008: Physician Insights on Key Attributes - Insomnia
Central Nervous System Insomnia or Sleep Disorders
|
|
|
|
